CASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $9 million versus the consensus estimate of $9.23 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.